Singapore markets closed

Atos SE (AEXAF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.16500.0000 (0.00%)
At close: 03:13PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.1650
Open2.1650
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.1650 - 2.1650
52-week range1.7900 - 16.5400
Volume279,432
Avg. volume3,745
Market cap241.521M
Beta (5Y monthly)1.39
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date14 May 2021
1y target estN/A
  • GlobeNewswire

    Introducing Eviden's new AI computing portfolio - the ultimate solution to unlock AI’s full potential

    BullSequana AI 1200H BullSequana AI 1200H BullSequanaAI 1200H (2) BullSequana AI 1200 Eviden Press Release Introducing Eviden's new AI computing portfolio - the ultimate solution to unlock AI’s full potential Paris, France – May 2, 2024 – Eviden, the Atos Group business leading in advanced computing, today announces its new product line “BullSequana AI.” This full end-to-end offering includes five new AI server ranges optimized for AI workloads and is designed to cater to a diverse range of AI n

  • GlobeNewswire

    Market update - April 29

    Non-binding letter of intent received from the French state to acquire 100% of the Advanced Computing, Mission-Critical Systems and Cybersecurity Products activities of Atos SE’s BDS (Big Data & Security) business Indicative enterprise valuation between €700 million and €1 billionDue diligence phase to start shortly in view of the issuance of a confirmatory non-binding offer by early June 2024 Revision of the parameters of the financial restructuring framework presented on April 9, 2024, to refl

  • GlobeNewswire

    Atos reports first quarter 2024 performance

    Press Release Atos reports first quarter 2024 performance1 Q1 2024 Revenue €2,479m, down -2.6% organically Eviden down -3.9% organically, reflecting continued softness in Americas and the UKTech Foundations down -1.5% organically, reflecting lower scope of work with certain customers in Americas and Central Europe Order entry of €1.6bn for a book-to-bill of 64%, compared with 73% in prior year Eviden book-to-bill at 83%, compared with 79% in prior year, driven by stronger demand in High-Performa